{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Gastroesophageal+Junction+%28GEJ%29+Adenocarcinoma&page=2",
    "query": {
      "condition": "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Gastroesophageal+Junction+%28GEJ%29+Adenocarcinoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:05:37.485Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03918499",
      "title": "IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVA Gastric Cancer AJCC v8",
        "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVB Gastric Cancer AJCC v8",
        "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Metastatic Gastric Adenocarcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Pathologic Stage IV Gastric Cancer AJCC v8",
        "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8",
        "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Recurrent Gastric Adenocarcinoma",
        "Recurrent Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytokine-based Biologic Agent IRX-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2019-04-19",
      "completion_date": "2023-02-09",
      "has_results": true,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-05-22T04:05:37.485Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Dallas, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03918499"
    },
    {
      "nct_id": "NCT04499924",
      "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Esophageal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "tucatinib",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "tucatinib placebo",
          "type": "OTHER"
        },
        {
          "name": "trastuzumab placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2021-03-22",
      "completion_date": "2024-04-17",
      "has_results": true,
      "last_update_posted_date": "2025-01-22",
      "last_synced_at": "2026-05-22T04:05:37.485Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04499924"
    },
    {
      "nct_id": "NCT04014075",
      "title": "DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma Gastric Stage IV With Metastases",
        "Adenocarcinoma - GEJ"
      ],
      "interventions": [
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2019-11-26",
      "completion_date": "2024-02-13",
      "has_results": true,
      "last_update_posted_date": "2025-04-03",
      "last_synced_at": "2026-05-22T04:05:37.485Z",
      "location_count": 20,
      "location_summary": "Duarte, California • Los Angeles, California • Monterey, California + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04014075"
    },
    {
      "nct_id": "NCT03821233",
      "title": "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-expressing Cancers"
      ],
      "interventions": [
        {
          "name": "ZW49",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zymeworks BC Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2019-04-15",
      "completion_date": "2024-10-08",
      "has_results": false,
      "last_update_posted_date": "2025-01-29",
      "last_synced_at": "2026-05-22T04:05:37.485Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03821233"
    },
    {
      "nct_id": "NCT07488676",
      "title": "A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma",
        "Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "ASP546C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2026-03-20",
      "completion_date": "2029-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-05-22T04:05:37.485Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07488676"
    },
    {
      "nct_id": "NCT00514020",
      "title": "Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "polymorphism analysis",
          "type": "GENETIC"
        },
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2007-08",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2012-11-01",
      "last_synced_at": "2026-05-22T04:05:37.485Z",
      "location_count": 5,
      "location_summary": "St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00514020"
    },
    {
      "nct_id": "NCT01395537",
      "title": "Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Esophagus",
        "Adenocarcinoma of the Gastroesophageal Junction"
      ],
      "interventions": [
        {
          "name": "Carboplatin AUC",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2011-08",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-05-22T04:05:37.485Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01395537"
    },
    {
      "nct_id": "NCT00940225",
      "title": "Study of Cabozantinib (XL184) in Adults With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 730,
      "start_date": "2009-09",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-05-22T04:05:37.485Z",
      "location_count": 34,
      "location_summary": "Scottsdale, Arizona • Sacramento, California • San Francisco, California + 30 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00940225"
    },
    {
      "nct_id": "NCT07284186",
      "title": "First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Esophageal Squamous Cell Carcinoma",
        "Gastric Adenocarcinoma",
        "Gastric Squamous Cell Carcinoma",
        "Gastroesophageal Junction (GEJ) Adenocarcinoma",
        "Metastatic Solid Tumor",
        "Non-Small Cell Lung Carcinoma",
        "Esophageal Adenocarcinoma",
        "SMARCA4 Mutation",
        "Gastroesophageal Junction Squamous Cell Carcinoma",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PLX-61639",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Plexium, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2025-12-01",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-22T04:05:37.485Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Orange, California + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07284186"
    },
    {
      "nct_id": "NCT04060342",
      "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma",
        "Esophageal Adenocarcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Triple Negative Breast Cancer",
        "Castration-resistant Prostate Cancer",
        "Microsatellite Stable Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Small-cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Urothelial Carcinoma",
        "Renal Cell Carcinoma",
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "GB1275",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel and gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2019-08-13",
      "completion_date": "2022-04-11",
      "has_results": false,
      "last_update_posted_date": "2022-08-18",
      "last_synced_at": "2026-05-22T04:05:37.485Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04060342"
    }
  ]
}